Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) shares, rose in value on Wednesday, 06/22/22, with the stock price up by 4.93% to the previous day's close as strong demand from buyers drove the stock to $25.12. Zentalis Pharmaceuticals Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. This is a -1.75% down since the beginning of the trading day. Weighted Alpha: A measure of how much a stock or commodity has risen or fallen over a one-year period. About the Company What analysts think ZNTL will be worth. T +1 212 433-3791 www.zentalis.com Sector Healthcare Industry Biotechnology Most Recent Earnings Mar 31, 2022 Fiscal Year End Dec 31, 2022 Stock Type Distressed Employees 177 Sponsor Center. Zentalis Pharmaceuticals is selling for 48.38 as of the 6th of April 2022.

Zentalis Pharmaceuticals, Inc. (ZNTL) has been beaten down lately with too much selling pressure. Score: 2.542.

About Zentalis Pharmaceuticals. Weaker Stock ZNTL: #1467. It was founded 2014 and headquartered in New York, United States. Company's stock value dipped to $25.96 during the trading on the day. ZNTL: Get the latest Zentalis Pharmaceuticals Inc stock price and detailed information including ZNTL realtime prices, CAGR, performance, comparison with BTC and other assets Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock. According to the issued ratings of 6 analysts in the last year, the consensus rating for Zentalis Pharmaceuticals stock is Buy based on the current 6 buy ratings for ZNTL. Advice was also provided on public company representation matters led by partner Jenna Cooper, with associates Nicole McNeil and Hamna Ahmad. Get Zentalis Pharmaceuticals Inc (ZNTL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. The stock's last close p. 1 year ago - Benzinga Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock News Zentalis Pharmaceuticals Inc. No significant news for ZNTL in the past two years. The stock has traded between $22.64 and $26.38 so far today. Cancel. (NASDAQ: ZNTL) Zentalis Pharmaceuticals's current Earnings Per Share (EPS) is -$3.87. Current $21.67. Zentalis Pharmaceuticals Inc is a biotechnology business based in the US. Find real-time ZNTL - Zentalis Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. 28/06/2022 14:15:17 1-888-992-3836 Free . What is ZNTL's Earnings Per Share (EPS) forecast for 2022-2024? Buy. . The average 12 month price objective among brokerages that have issued a report . Closing stock price (17-Jun-2022) 22.1: Cash (31-Dec-2019) 67.2m: Zentalis Pharmaceuticals's current market capitalization is $1 b . At the very opening of the session, the stock price was $22.34 and reached a high price of $25.32, prior to closing the session it reached the value of $22.33. 29.03 +0.93 (3.31%) At close: Jul 1, 2022 4:00 PM. Get the latest Zentalis Pharmaceuticals detailed stock quotes, stock trade data, stock price info, and performance analysis, including Zentalis Stock investment advice, charts, stats and more. Zentalis Pharmaceuticals price target. The Score for ZNTL is 45, which is 10% below its historic median score of 50, and infers higher risk than normal. Its last market close was $50.33 - a decrease of 21.11% over the previous week. Both the companies also plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic . 05 May. Rooms Shows Rankings Earnings Newsletters Shop. 1-212-433-3791 info@zentalis.com NEW YORK and SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small. Fact checked. Zentalis Pharmaceuticals stock rating. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. Zentalis Pharmaceuticals has raised a total of $517.1M in funding over 5 rounds. It is calculated by multiplying the stock price by the number of shares outstanding. $92.80. Get the latest Zentalis Pharmaceuticals Inc (ZNTL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the closing of. is the total value of all of a company's outstanding shares. Zentalis Pharmaceuticals has risen higher in 1 of those 1 years over the subsequent 52-week period, corresponding to a historical accuracy of 100% Zentalis Pharmaceuticals, Inc. is incorporated in the state of Delaware. Shares of Zentalis Pharmaceuticals, Inc. ( ZNTL) gained nearly 14% on Wednesday morning after the clinical-stage biopharmaceutical company announced a $25 million equity investment from Pfizer Inc. (PFE). Trending now. Barchart takes this Alpha and weights this, assigning more weight to recent activity, and less . Using our industry expertise, we have developed an integrated approach to identify and overcome the limitations of current cancer therapeutics, enabling us to design better small molecules for improved . This net worth approximation does not reflect any other assets that Dr. Bunker may own. . Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. On average, they predict Zentalis Pharmaceuticals' stock price to reach $74.43 in the next twelve months. Free forex prices, toplists, indices and lots more. Learn More about Melissa B. Epperly's net worth. Zentalis Pharmaceuticals employs 177 staff and has a market cap (total outstanding shares value) of 0.00. NASDAQ 0.00%. Complete Zentalis Pharmaceuticals Inc. stock information by Barron's. View real-time ZNTL stock price and news, along with industry-best analysis. It is focused on discovering and developing small molecule therapeutics targeting cancers. That means that investors have to take special care when deciding whether or not to invest in pharmaceutical companies and the like. Sign Up. Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday. List of events that could affect ZNTL stock. NASDAQ Stock Exchange > Watchlist. . Sign Up. Ticker: ZNTL. Get Zentalis Pharmaceuticals Inc (ZNTL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. If you had invested in ZENTALIS PHARMACEUTICALS stock at $23.20, your return over the last 2 years would . USD. Report $29.03 (3.31%) Volume: 415.233k. Rooms Shows Rankings Earnings Newsletters Shop. Get Zentalis Pharmaceuticals (ticker: ZNTL) real-time share value, investment, rating and financial market information from Capital. Zentalis Pharmaceuticals Llc is a biotechnology business based in the US. Following the completion of the transaction, the chief operating officer now owns 110,000 shares in the company, valued at $3,307,700. Ms. Epperly owns 247,414 shares of Zentalis Pharmaceuticals stock worth more than $4,686,021 as of May 13th. It is calculated by multiplying the stock price by the number of shares outstanding. For More Information. Best predictor for any stock is listed at the stock pages. View the latest Zentalis Pharmaceuticals Inc. (ZNTL) stock price, news, historical charts, analyst ratings and financial information from WSJ. Formula: Market Cap = Stock Price * Shares Outstanding.

Zentalis Pharmaceuticals Inc (ZNTL) stock is trading at $26.52 as of 4:00 PM on Tuesday, May 17, an increase of $2.11, or 8.64% from the previous closing price of $24.41. Phone Number 212-433-3791. One such company that has been circulating in the news a lot lately is Zentalis Pharmaceuticals. Stronger Stock . On average, analysts forecast that ZNTL's EPS will . The company's lead programs. When the transactions were called off in the previous session, Stock hit the highs of $29.29, after setting-off with the price of $26.56. Zentalis Pharmaceuticals shares (ZNTL) are listed on the NASDAQ and all prices are listed in US Dollars. S&P 500 0.00%.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Sales of common stock, if any, pursuant to the Sales Agreement, may be made in sales deemed to be an "at the market offering" as defined in . S&P 500 0.00%. The average twelve-month price prediction for Zentalis Pharmaceuticals is $74.43 with a high price target of $120.00 and a low price target of $51.00. Zentalis Pharmaceuticals Inc. Stock Forecast NASDAQ:ZNTL BUY SELL. What analysts recommend for ZNTL stock, on a scale from 1 (buy) to 5 (sell). Get the latest Zentalis Pharmaceuticals Inc (ZNTL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Rating) COO Kevin D. Bunker sold 25,000 shares of the firm's stock in a transaction on Tuesday, July 5th.The stock was sold at an average price of $30.07, for a total value of $751,750.00. The average Zentalis Pharmaceuticals stock price prediction forecasts a potential upside of 206.58% from the current ZNTL share price of $29.03. . Real-time trade and investing ideas on Zentalis Pharmaceuticals Inc ZNTL from the largest community of traders and investors. The stock has traded between $24.77 and $27.61 so far today. Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Rating) has been assigned an average rating of "Buy" from the seven brokerages that are presently covering the stock, Marketbeat reports. The stock has traded between $29.51 and $87.19 in the past 52 week period. ZENTALIS PHARMACEUTICALS stock was originally listed at a price of $23.20 in Apr 3, 2020. In addition, Zentalis has granted the underwriters a 30-day option to purchase up to an additional 618,750 shares of its common stock at the public offering price, less underwriting discounts and . 10835 Road to the Cure Suite 205 San Diego, CA 92121. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid . Find real-time ZNTL - Zentalis Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. For the readers interested in the stock health of Zentalis Pharmaceuticals Inc. (ZNTL). exchange on which registered Common Stock, $0.001 par value ZNTL The Nasdaq Global Market per share Indicate by check mark whether the registrant is an emerging . Zentalis Pharmaceuticals has 62 employees across 2 locations. 29.03 +0.93 (3.31%) At close: Jul 1, 2022 4:00 PM. . The stock had previously closed at $21.38, but opened at $22.24.

Foghorn Therapeutics presently has a consensus price target of $24.00, suggesting a potential upside of 84.05%. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the . Zentalis Pharmaceuticals Inc.'s (NASDAQ: ZNTL) Stock Price Will Be Bearish Or Bullish In 2022 stocksregister 21 hrs ago Looking Closely at the Growth Curve for Zentalis Pharmaceuticals Inc. (ZNTL) The stock opened Monday's trading at $33.00 after closing last trading day at $33.97. If you want to know more, keep reading.

Zentalis Pharmaceuticals Inc 30.66 1.63 (5.62%) Watch. With ZENTALIS PHARMACEUTICALS stock trading at $21.38 per share, the total value of ZENTALIS PHARMACEUTICALS stock (market capitalization) is $996.95M. Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer. Dr. Bunker owns 135,000 shares of Zentalis Pharmaceuticals stock worth more than $3,686,850 as of June 23rd. DOW 0.00%. In Thousands, USD TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019; EV: As a result of the Corporate Conversion, all holders of units of Zentalis Pharmaceuticals, LLC became holders of shares of common stock of Zentalis Pharmaceuticals, Inc. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.

DOW 0.00%. Events. documents---0.058352947235107. The stock's lowest day price was 46.96. Zentalis Pharmaceuticals, Inc. (ZNTL) has been beaten down lately with too much selling pressure. Cancel.

Seeking Alpha 37d Zentalis Pharmaceuticals appoints. Complete Zentalis Pharmaceuticals Inc. stock information by Barron's. View real-time ZNTL stock price and news, along with industry-best analysis. April 27, 2022 - 7:00 am. Zentalis Pharmaceuticals is registered under the ticker NASDAQ:ZNTL . The stock touched a low price of $21.92.Rece In connection with the Corporate . The estimated net worth of Kevin D. Bunker is at least $3.69 million as of April 11th, 2022. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-3.85 Market Cap $1.25 B Shares Outstanding 55.91 M Public Float. Actively observing the price movement in the last trading, the stock closed the session at Updated Jan 11, 2022. USD. Latham & Watkins LLP represents Zentalis Pharmaceuticals, Inc. in the offering with a corporate team led by partner Nathan Ajiashvili, with associates Salvatore Vanchieri, Matt DeSilva, and Darby Dietrich. Trending now. The current Zentalis Pharmaceuticals [ ZNTL] share price is $28.34. The company belongs in the Biotechnology industry, Healthcare sector and employs 110 people. Contact Email info@zentalis.com. Target $92.80. Zentalis Pharmaceuticals, LLC (ZNTL) Stock Price, News & Info | The Motley Fool Zentalis Pharmaceuticals, LLC (ZNTL) Nasdaq Global Market ZNTL $23.94 $1.83 8.3% Price as of June 21, 2022, 4:00 p.m..